key: cord-0725898-qgsi7x8a authors: Al-amri, Sawsan S.; Hashem, Anwar M. title: Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA date: 2019-09-14 journal: MERS Coronavirus DOI: 10.1007/978-1-0716-0211-9_11 sha: 025931fab21cf63c99d33a3fc8e2818c1b6c86be doc_id: 725898 cord_uid: qgsi7x8a Indirect enzyme-linked immunosorbent assay (ELISA) enables detection and quantification of antigen-specific antibodies in biological samples such as human or animal sera. Most current MERS-CoV serological assays such as neutralization, immunofluorescence, or protein microarray rely on handling of live MERS-CoV in high containment laboratories, highly trained personnel as well as the need for expensive and special equipment and reagents representing a hurdle for most laboratories especially when resources are limited. In this chapter, we describe a validated and optimized indirect ELISA protocol based on recombinant S1 subunit (amino acids 1–725) of MERS-CoV for qualitative and quantitative determination of MERS-CoV-binding antibodies. validated using a large number of well-characterized human serum samples [8] and could be adapted by any laboratory especially that all required reagents are commercially available. Prepare all solutions using deionized water and store them at room temperature or 4 C. Diligently follow all waste disposal regulations when disposing waste materials. Carry out all procedures at room temperature unless otherwise specified. Detection of MERS-CoV S1-Specific Antibodies 1. Dilute recombinant MERS-CoV S1 subunit protein (antigen) to a final concentration of 1 μg/mL using 1Â PBS buffer. You need 10 mL per 96-well ELISA plate. 2. Transfer the diluted recombinant protein to a clean reagent reservoir and coat the 96-well ELISA plate with 100 μL/well using multichannel pipette. 3. Seal the plate using ELISA plate sealing cover (adhesive film) and incubate at 4 C overnight to allow the antigen to adsorb to the well surface (see Note 4). 4. Wash the 96-well ELISA plate three times using automated 96-well plate washer with PBST. Use 350 μL wash buffer per well (see Note 5). After washing, invert the plate and tap it firmly on an absorbent paper to remove any residual liquid. 6. Block the plate with blocking buffer (300 μL/well), seal the plate and incubate for 1 h at room temperature (see Note 6). 8. Wash the plate as indicated in steps 4 and 5. 9. Add 100 μL of diluted serum samples or controls to each well, seal the plate, and incubate at 37 C for 1 h (see Note 9). 10. During incubation, dilute appropriate HRP-conjugated secondary antibody in blocking solution according to manufacturer's instructions. 11. Wash the plate as indicated in steps 4 and 5 (see Note 10). 12. Add 100 μL of diluted secondary antibody to each well and incubate at 37 C for 1 h. 13. Wash the plate as indicated in steps 4 and 5 (see Note 11). 14. Add 100 μL of TMB substrate to each well and incubate at room temperature for 30 min in the dark for colorimetric development (see Notes 12 and 13). 15. Stop reaction with equal volume of TMB BlueSTOP solution. 16. Read absorbance in the plate on automated microplate reader at 630 nm (see Note 14) . 17. Samples with absorbance above the cutoff value of 0.34 are considered positive (assay sensitivity and specificity are 94.9% and 95.2%, respectively [8] ) (see Note 15). Titration of MERS-CoV S1-Specific Antibodies 1. Coat and block the plate as indicated in the steps 1-6 in Subheading 3.1. 2. In a new sterile U-shaped 96-well plate, add 297 μL blocking buffer to all wells in column 1 (see Note 16). 3. Add 150 μL blocking buffer to all remaining wells in the plate (Fig. 1 ). 4. Add 3 μL from each serum per well in all wells in column 1 to have 1:100 dilution (Fig. 1) . Test each serum sample in duplicates (see Notes 7 and 8). Add 297 μL blocking buffer to wells in column 1 Add 150 μL blocking buffer to all wells Fig. 1 Plate layout for serum sample serial dilution 5. Perform twofold serial dilutions by transferring 150 μL progressively from column to column using a multichannel pipette (Fig. 1 ). 6. During each dilution step mix well by pipetting eight times up and down (see Note 17). 7. Discard the final 150 μL after column 12. 8. Wash the incubated plate as indicated in steps 4 and 5 in Subheading 3.1 to remove blocking buffer. 9. Add 100 μL from each dilution to each well using a multichannel pipette, seal the plate, and incubate at 37 C for 1 h (see Note 17). 10. Continue using steps 10-16 from Subheading 3.1 and save the results. 11. The last dilution needs to reach a signal equivalent to the background reading from blocking buffer without serum (see Note 18). 12. The every last dilution that gives twice the signal of the background indicates the end-point titer of the sample; otherwise, antibody titer can be determined using four-parameter logistic (4PL) regression curve in SigmaPlot or GraphPad Prism software. 1. Use different reagent reservoir for each buffer. 2. Alternatively, carbonate-bicarbonate buffer (50 mM), pH 9.6, could be used as coating buffer: Prepare buffer by adding 2.88 g of sodium bicarbonate (NaHCO 3 ) and 1.67 g of sodium carbonate (Na2CO3) to~980 mL water. Adjust the pH to 9.6 with HCl if needed and complete the volume to 1 L with water. 3. Measure 100 mL of 1Â PBST to a 100 mL graduated cylinder and transfer the volume to a glass bottle. Transfer 5 g skim milk powder into the bottle and stir until dissolved. 4. Coating buffer helps to bind antigen to the wells. During coating, sealing the plates will help prevent any reagents from evaporating overnight when leaving them in the refrigerator. 5. Washing the 96-well ELISA plate with PBST will help remove any unbound antigens from the wells. 6. Blocking helps in preventing nonspecific binding of detection antibodies to the microplate surface, reducing signal background and improving the signal-to-noise ratio. Blocking could be done at 4 C for overnight. 7. Use heat-inactivated serum samples at 56 C for 30 min. 8. Mix thawed serum samples before and after dilution with a vortex for about 10 s. 9. No primary antibody control could be included by adding 100 μL of blocking buffer per well. 10. This washing step will help removing nonspecific or unbound antibodies. 11. This washing step is critical to reduce background signal. 12. Warm TMB substrate and stop solution to room temperature before use. Never pipette directly from the bottle. Pour out needed amount into a plastic reservoir. Do not return excess to the primary container. 13. Avoid shaking. 14. Stopped reactions should be read within 30 min. TMB Blue-STOP allows the chromophore to remain blue, instead of turning yellow. If using a stop solution resulting in a yellow reaction, read the plate at 450 nm. 15. Samples with absorbance values that fall 0.26 and 0.34 should be considered "indeterminate" and should be validated with other methods if possible. 16. Do steps 2-7 during incubation with blocking buffer. 17. Change pipette tips between wells. 18. Higher dilutions of the samples may be required in case the last dilution did not reach a signal equivalent to the background. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection Development and validation of different indirect ELISAs for MERS-CoV serological testing This work was supported by King Abdulaziz City for Science and Technology (KACST) through the MERS-CoV research grant program (number 09-1 to AMH), which is a part of the Targeted Research Program.